<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885179</url>
  </required_header>
  <id_info>
    <org_study_id>20-32291</org_study_id>
    <nct_id>NCT04885179</nct_id>
  </id_info>
  <brief_title>SPL Insufficiency Syndrome (SPLIS): a SPLIS Observational Study and Patient Registry (International)</brief_title>
  <acronym>SPLIS-OSPRI</acronym>
  <official_title>Sphingosine Phosphate Lyase Insufficiency Syndrome - Observational Study and Patient Registry (International)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol aims to characterize the natural history of sphingosine phosphate lyase&#xD;
      insufficiency syndrome (SPLIS) and to create a SPLIS patient registry. Medical records,&#xD;
      radiological and pathology results, blood test results, and genetic information will be&#xD;
      collected. Samples of blood, cheek cells, urine and stool may be collected for analysis. If a&#xD;
      skin biopsy has been performed for medical care, cells from the biopsy may be analyzed. No&#xD;
      treatment or other intervention is involved in this study. However, the effect of treatments&#xD;
      administered by the patient's physician may be detected and monitored based on changes in the&#xD;
      blood or urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol aims to characterize the natural history of sphingosine phosphate lyase&#xD;
      insufficiency syndrome (SPLIS) and to create a SPLIS patient registry. SPLIS is a recently&#xD;
      discovered genetic disease caused by recessive mutations in the SGPL1 gene. SPLIS can have&#xD;
      effects on the kidney, adrenal gland, brain, skin, and blood cells. Some patients with SPLIS&#xD;
      do not survive beyond infancy, whereas others live to adulthood. By monitoring the natural&#xD;
      history of SPLIS over time in affected patients, the investigators will establish a clinical&#xD;
      baseline that reflects how the disease progresses over time. This information may be useful&#xD;
      in future clinical trials. The results may reveal which types of SGPL1 mutations correlate&#xD;
      with best and worst patient outcomes. Some SPLIS patients are current on a regimen of high&#xD;
      dose vitamin B6 supplementation on the advice of their treating physician. By including&#xD;
      patients treated with B6, our study may provide evidence for the impact of B6 treatment on&#xD;
      biochemical and blood markers of the disease. Our overall goals are to characterize the&#xD;
      clinical, biochemical and metabolic manifestations of SPLIS and how these manifestations&#xD;
      change over time within individuals with this condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>0-99 years</time_frame>
    <description>The primary outcome of this study is survival (age at death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of nephrotic syndrome</measure>
    <time_frame>0-99 years</time_frame>
    <description>Age at onset of proteinuria greater than 3.5 grams per 24h</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Onset of primary adrenal insufficiency</measure>
    <time_frame>0-99 years</time_frame>
    <description>Age at onset of glucocorticoid insufficiency with or without other endocrine defects</description>
  </other_outcome>
  <other_outcome>
    <measure>Responsiveness of blood sphingolipid levels to vitamin B6 supplementation</measure>
    <time_frame>0-99 years</time_frame>
    <description>Changes in blood sphingolipid levels before and after caring physician-initiated vitamin B6 supplementation</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin fibroblast sphingolipid levels in response to vitamin B6</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Skin fibroblast sphingolipid levels compared by liquid chromatography/mass spectrometry in medium containing various forms of vitamin B6 or lacking vitamin B6.</description>
  </other_outcome>
  <other_outcome>
    <measure>Responsiveness of absolute lymphocyte count to vitamin B6 supplementation</measure>
    <time_frame>0-99 years</time_frame>
    <description>Changes in blood absolute lymphocyte count before and after caring physician-initiated vitamin B6</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sphingolipidoses</condition>
  <condition>Enzyme Deficiency</condition>
  <arm_group>
    <arm_group_label>Individuals with SPLIS</arm_group_label>
    <description>Individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents of individuals with SPLIS</arm_group_label>
    <description>Parents of individuals diagnosed with SPLIS based on genetic testing that confirms bi-allelic pathogenic variants in SGPL1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>age and gender-matched controls</arm_group_label>
    <description>The investigators will attempt to collect biological specimens from individuals closely matched to SPLIS patient cohort by age and gender. This group may include siblings, cousins, and unrelated healthy children and adults.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>No interventions are involved in this observational study.</description>
    <arm_group_label>Individuals with SPLIS</arm_group_label>
    <arm_group_label>Parents of individuals with SPLIS</arm_group_label>
    <arm_group_label>age and gender-matched controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Leftover skin biopsy material or fibroblasts derived from skin biopsies obtained as part of&#xD;
      medical care may be used to create a cell line that will be analyzed and stored in a SPLIS&#xD;
      specimen bank at UCSF.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        SPLIS is a genetic disorder caused by recessive mutations in SGPL1. The study population&#xD;
        includes individuals with confirmed bi-allelic mutations in SGPL1, regardless of age,&#xD;
        gender, disease manifestations, or treatments received. Some patients with SPLIS will have&#xD;
        kidney failure, adrenal insufficiency and/or neurological problems. Parents, family members&#xD;
        and unrelated healthy individuals enrolled during routine health appointments, elective&#xD;
        surgical procedures and other medical interactions will be included as healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Individuals of all ages diagnosed with SPLIS based on bi-allelic&#xD;
        pathogenic variants of SGPL1, including children and neonates, as well as family members or&#xD;
        caregivers, healthy volunteers and individuals with other sphingolipidoses.&#xD;
&#xD;
        Exclusion Criteria: the investigators will not include:&#xD;
&#xD;
          -  prisoners&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  healthy volunteers with:&#xD;
&#xD;
               -  diabetes,&#xD;
&#xD;
               -  infection,&#xD;
&#xD;
               -  fever,&#xD;
&#xD;
               -  known HIV/AIDS,&#xD;
&#xD;
               -  cardiac disease&#xD;
&#xD;
               -  or anemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie D Saba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie D Saba, MD, PhD</last_name>
    <phone>510-414-6317</phone>
    <email>Julie.Saba@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Y Lee, PhD</last_name>
    <phone>510-590-8292</phone>
    <email>Joanna.Lee@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie D Saba, MD, PhD</last_name>
      <phone>510-414-6317</phone>
      <email>Julie.Saba@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joanna Y Lee, PhD</last_name>
      <phone>510-590-8292</phone>
      <email>Joanna.Lee@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rarediseases.info.nih.gov/diseases/13818/sphingosine-phosphate-lyase-insufficiency-syndrome</url>
    <description>Genetic and Rare Disease (GARD) Information Center, National Center for Advancing Translational Sciences</description>
  </link>
  <reference>
    <citation>Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi WI, Shril S, Ashraf S, Tan W, Rao J, Airik M, Schapiro D, Braun DA, Sadowski CE, Widmeier E, Jobst-Schwan T, Schmidt JM, Girik V, Capitani G, Suh JH, Lachaussée N, Arrondel C, Patat J, Gribouval O, Furlano M, Boyer O, Schmitt A, Vuiblet V, Hashmi S, Wilcken R, Bernier FP, Innes AM, Parboosingh JS, Lamont RE, Midgley JP, Wright N, Majewski J, Zenker M, Schaefer F, Kuss N, Greil J, Giese T, Schwarz K, Catheline V, Schanze D, Franke I, Sznajer Y, Truant AS, Adams B, Désir J, Biemann R, Pei Y, Ars E, Lloberas N, Madrid A, Dharnidharka VR, Connolly AM, Willing MC, Cooper MA, Lifton RP, Simons M, Riezman H, Antignac C, Saba JD, Hildebrandt F. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017 Mar 1;127(3):912-928. doi: 10.1172/JCI89626. Epub 2017 Feb 6.</citation>
    <PMID>28165339</PMID>
  </reference>
  <reference>
    <citation>Prasad R, Hadjidemetriou I, Maharaj A, Meimaridou E, Buonocore F, Saleem M, Hurcombe J, Bierzynska A, Barbagelata E, Bergadá I, Cassinelli H, Das U, Krone R, Hacihamdioglu B, Sari E, Yesilkaya E, Storr HL, Clemente M, Fernandez-Cancio M, Camats N, Ram N, Achermann JC, Van Veldhoven PP, Guasti L, Braslavsky D, Guran T, Metherell LA. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. 2017 Mar 1;127(3):942-953. doi: 10.1172/JCI90171. Epub 2017 Feb 6.</citation>
    <PMID>28165343</PMID>
  </reference>
  <reference>
    <citation>Weaver KN, Sullivan B, Hildebrandt F, Strober J, Cooper M, Prasad R, Saba J. Sphingosine Phosphate Lyase Insufficiency Syndrome. 2020 Oct 15. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from http://www.ncbi.nlm.nih.gov/books/NBK562988/</citation>
    <PMID>33074640</PMID>
  </reference>
  <reference>
    <citation>Choi YJ, Saba JD. Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism. Adv Biol Regul. 2019 Jan;71:128-140. doi: 10.1016/j.jbior.2018.09.004. Epub 2018 Sep 25. Review.</citation>
    <PMID>30274713</PMID>
  </reference>
  <reference>
    <citation>Zhao P, Liu ID, Hodgin JB, Benke PI, Selva J, Torta F, Wenk MR, Endrizzi JA, West O, Ou W, Tang E, Goh DL, Tay SK, Yap HK, Loh A, Weaver N, Sullivan B, Larson A, Cooper MA, Alhasan K, Alangari AA, Salim S, Gumus E, Chen K, Zenker M, Hildebrandt F, Saba JD. Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation. J Inherit Metab Dis. 2020 Sep;43(5):1131-1142. doi: 10.1002/jimd.12238. Epub 2020 May 4.</citation>
    <PMID>32233035</PMID>
  </reference>
  <reference>
    <citation>Martin KW, Weaver N, Alhasan K, Gumus E, Sullivan BR, Zenker M, Hildebrandt F, Saba JD. MRI Spectrum of Brain Involvement in Sphingosine-1-Phosphate Lyase Insufficiency Syndrome. AJNR Am J Neuroradiol. 2020 Oct;41(10):1943-1948. doi: 10.3174/ajnr.A6746. Epub 2020 Aug 27.</citation>
    <PMID>32855188</PMID>
  </reference>
  <reference>
    <citation>Zhao P, Tassew GB, Lee JY, Oskouian B, Muñoz DP, Hodgin JB, Watson GL, Tang F, Wang JY, Luo J, Yang Y, King S, Krauss RM, Keller N, Saba JD. Efficacy of AAV9-mediated SGPL1 gene transfer in a mouse model of S1P lyase insufficiency syndrome. JCI Insight. 2021 Apr 22;6(8). pii: 145936. doi: 10.1172/jci.insight.145936.</citation>
    <PMID>33755599</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPLIS</keyword>
  <keyword>sphingosine phosphate lyase</keyword>
  <keyword>SGPL1</keyword>
  <keyword>sphingolipidosis</keyword>
  <keyword>steroid-resistant nephrotic syndrome</keyword>
  <keyword>primary adrenal insufficiency</keyword>
  <keyword>neurological defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sphingolipidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

